Physician profile
Matthew Thomas Dewitt
NPI 1700882396
$4,977.20
in general payments reported to CMS, 2019-2025
10 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2021: $25.99 · 2022: $1,314 · 2023: $117 · 2024: $1,087 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $1,056 · Food and Beverage: $570 · Travel and Lodging: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $1,056.00 |
| Food and Beverage | $569.58 |
| Travel and Lodging | $511.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Extremity Medical | $1,500.00 | 2019 | |
| Crossroads Orthopedics, LLC | $1,200.00 | 2022 | |
| Convatec INC. | $1,073.66 | 2024 | |
| Medline Industries LP | $886.14 | 2025 | |
| Organogenesis INC. | $148.68 | 2022-2025 | Puraply, Puraply Wound Matrix |
| Depuy Synthes Sales INC. | $119.36 | 2021-2023 | Dynaforce |
| Medtronic, INC. | $14.70 | 2025 | Intellis Adaptivestim |
| Solventum Corporation | $13.60 | 2024 | Activ.A.C., Promogran Prisma |
| Djo, LLC | $11.05 | 2021 | |
| Kerecis Limited | $10.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.